Literature DB >> 18997292

Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta aggregation.

Ian Macreadie1, Mehrnoush Lotfi-Miri, Sameera Mohotti, Deborah Shapira, Louise Bennett, Joseph Varghese.   

Abstract

Previously in the search for chemopreventatives for Alzheimer's disease (AD), microbial cells with amyloid-beta (Abeta) protein fusions have been used to screen for compounds that reduce the aggregation, misfolding or oligomerization of Abeta. In the current study, such a system has been used to look at the effect of folate, whose deficiency has been associated with AD. A folate-deficient yeast strain producing Abeta fused to green fluorescent protein (GFP) that spontaneously misfolds/aggregates and suppresses green fluorescence was used to examine the effects of folinic acid on Abeta-GFP fluorescence. At levels that did not affect growth or plasmid stability, increasing levels of folinic acid led to increasing green fluorescence, suggesting folate can assist with preventing Abeta-misfolding/aggregation. This result supports a protective role for folate and suggests that yeast assays may provide significant new approaches for testing of AD chemopreventatives.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997292     DOI: 10.3233/jad-2008-15305

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  9 in total

Review 1.  Application of yeast to studying amyloid and prion diseases.

Authors:  Yury O Chernoff; Anastasia V Grizel; Aleksandr A Rubel; Andrew A Zelinsky; Pavithra Chandramowlishwaran; Tatiana A Chernova
Journal:  Adv Genet       Date:  2020-05-04       Impact factor: 1.944

2.  Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Authors:  Afsaneh Porzoor; Joanne M Caine; Ian G Macreadie
Journal:  Prion       Date:  2014       Impact factor: 3.931

3.  Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization.

Authors:  Sei-Kyoung Park; Scott D Pegan; Andrew D Mesecar; Lisa M Jungbauer; Mary Jo LaDu; Susan W Liebman
Journal:  Dis Model Mech       Date:  2011-08-02       Impact factor: 5.758

Review 4.  Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae.

Authors:  Catarina Pimentel; Liliana Batista-Nascimento; Claudina Rodrigues-Pousada; Regina A Menezes
Journal:  Oxid Med Cell Longev       Date:  2012-06-03       Impact factor: 6.543

5.  Inhibition of Aβ42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs.

Authors:  Sei-Kyoung Park; Kiira Ratia; Mariam Ba; Maria Valencik; Susan W Liebman
Journal:  Microb Cell       Date:  2016-01-20

Review 6.  Recent Insights on Alzheimer's Disease Originating from Yeast Models.

Authors:  David Seynnaeve; Mara Del Vecchio; Gernot Fruhmann; Joke Verelst; Melody Cools; Jimmy Beckers; Daniel P Mulvihill; Joris Winderickx; Vanessa Franssens
Journal:  Int J Mol Sci       Date:  2018-07-03       Impact factor: 5.923

Review 7.  Contribution of yeast models to neurodegeneration research.

Authors:  Clara Pereira; Cláudia Bessa; Joana Soares; Mariana Leão; Lucília Saraiva
Journal:  J Biomed Biotechnol       Date:  2012-07-15

8.  Genome-wide analysis of Saccharomyces cerevisiae identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid-β42: importance of lipid homeostasis.

Authors:  S Nair; M Traini; I W Dawes; G G Perrone
Journal:  Mol Biol Cell       Date:  2014-05-28       Impact factor: 4.138

Review 9.  Yeast Models for Amyloids and Prions: Environmental Modulation and Drug Discovery.

Authors:  Tatiana A Chernova; Yury O Chernoff; Keith D Wilkinson
Journal:  Molecules       Date:  2019-09-18       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.